Lacosamide for Focal Seizures in Adults
Lacosamide is an effective adjunctive antiseizure medication for focal seizures in adults, initiated at 100 mg/day (50 mg twice daily) and titrated weekly by 100 mg/day increments to a maintenance dose of 200-400 mg/day based on tolerability and seizure control, with dose reductions required for severe renal impairment (creatinine clearance <30 mL/min) and avoidance recommended in patients with cardiac conduction abnormalities or severe hepatic dysfunction.
Dosing Guidelines
Standard Dosing
- Initiation: Start at 100 mg/day (50 mg twice daily) 1
- Titration: Increase weekly by 100 mg/day increments over 12 weeks 2, 3
- Maintenance: Target dose range 200-400 mg/day 1, 3
- Route: Both oral and IV formulations available with equivalent tolerability profiles 1
The evidence shows that 400 mg/day provides optimal balance between efficacy and tolerability, with median seizure frequency reductions of 37.3% versus 20.8% for placebo 3. While 600 mg/day may offer additional benefit for some patients (37.8% reduction), it comes with increased dose-related adverse effects 3.
Therapeutic Drug Monitoring
Recent evidence challenges the traditional reference range. The optimal therapeutic range appears to be 8.0-10.5 µg/mL rather than the widely cited 10-20 mg/L 4, 5. Blood levels above 12 mg/L are associated with significantly increased toxicity, with 41% of patients experiencing adverse effects at mean levels of 15.6 mg/L versus 12.6 mg/L in those without adverse effects 4.
Renal Dose Adjustments
Critical dosing modifications are required based on renal function 6, 7:
- Mild-to-moderate impairment (CrCl >30 mL/min): No adjustment needed, as total body clearance decreases by only ~20% 6
- Severe impairment (CrCl <30 mL/min): Maximum dose 300 mg/day 6, 7
- End-stage renal disease: Supplemental dose of up to 50% of divided daily dose recommended after hemodialysis, as approximately 50% of lacosamide is removed during 4-hour dialysis 6
The pharmacokinetic rationale: renal clearance accounts for ~30% of total body clearance in healthy individuals but drops to ~11% in severe renal impairment, with terminal half-life increasing proportionally 6.
Hepatic Dose Adjustments
Lacosamide should be avoided in severe hepatic dysfunction 7, 8. While specific dose adjustments for mild-to-moderate hepatic impairment are not well-established in the literature provided, the drug undergoes significant hepatic metabolism. The evidence suggests caution and potential dose reduction in any degree of hepatic impairment 7.
Cardiac Monitoring Requirements
ECG monitoring is essential before initiating lacosamide and during dose escalation in patients with:
- Known cardiac conduction problems (PR interval prolongation, AV block)
- Structural heart disease
- Ischemic heart disease
- Concomitant use of other sodium channel blockers 9, 8
Lacosamide causes dose-related PR interval prolongation 10, 8. The 2019 CAR T-cell therapy guidelines explicitly recommend avoiding lacosamide as a first-line antiseizure medication due to its unfavorable cardiotoxicity profile 9. This is particularly relevant in status epilepticus management, where alternative agents should be prioritized 9.
Common Adverse Effects
The most frequently reported adverse effects (≥5% incidence) include 1, 2:
- Dizziness (most common, dose-related)
- Headache
- Nausea and vomiting (dose-related)
- Somnolence
- Back pain
- Injection site reactions (IV formulation)
All adverse effects in controlled trials were mild-to-moderate in severity 1. However, serious adverse reactions require vigilance 8:
Serious Adverse Effects
- DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms) - use with extreme caution in patients with drug allergy history 8
- Psychiatric effects - avoid in patients with psychiatric disorder history or implement intensive monitoring for depression/psychosis 8
- Cardiac conduction disturbances - as discussed above 8
Withdrawal due to adverse effects occurred in 14% of patients in open-label trials, most commonly due to dizziness (6%), vomiting (2%), and tremor (2%) 2.
Alternative Therapies for Focal Seizures
When lacosamide is contraindicated or not tolerated, evidence-based alternatives include 1:
First-Line Alternatives
- Levetiracetam: 1,500 mg oral load or up to 60 mg/kg IV; well-tolerated with minimal drug interactions, no cardiac concerns 1
- Lamotrigine: Requires slow titration due to rash risk; 6.5 mg/kg single oral load only if previously on lamotrigine >6 months without rash history 1
Second-Line Alternatives
- Phenytoin/Fosphenytoin: 18-20 mg/kg loading dose; IV faster but more adverse effects than oral; requires cardiac monitoring 1
- Valproate: Up to 30 mg/kg IV at maximum rate 10 mg/kg/min; safe and well-tolerated 1
- Carbamazepine: 8 mg/kg oral suspension; 58% adverse effect rate limits use 1
Newer Alternatives
- Brivaracetam: Minimally affected by renal/hepatic impairment; favorable for organ dysfunction 7
- Perampanel: Requires strict dose caps in severe organ dysfunction 7
- Cenobamate: Contraindicated in severe organ dysfunction 7
Clinical Pitfalls and Caveats
Do not use the 10-20 mg/L reference range - this leads to unnecessary toxicity. Target 8.0-10.5 µg/mL for optimal efficacy with minimal adverse effects 4, 5.
Screen for cardiac disease before prescribing - lacosamide's PR interval prolongation can precipitate heart block in susceptible patients 9, 8.
Avoid abrupt discontinuation - withdrawal seizures have been reported 1.
Intermediate doses permitted during titration - for patients sensitive to new antiseizure medications, intermediate doses can be used for one week at each escalation step 2.
Hemodialysis patients require supplementation - do not forget the post-dialysis dose 6.
Monitor sodium levels - though less problematic than with eslicarbazepine, periodic monitoring is prudent 8.